| Washington University in St. Louis | |
|---|---|
| Logo placeholder | |
| Location | St. Louis, MO, USA |
| Type | University |
| Website | https://wustl.edu/ |
| Focus Areas | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Biomarkers](/mechanisms/biomarkers-ad) |
| Departments | Department of Neurology |
Washington University School of Medicine in St. Louis is one of the nation's leading research institutions, consistently ranked among the top medical schools for research funding and excellence[1]. The university's Knight Initiative for Brain Resilience and Department of Neurology house comprehensive research programs in Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
Washington University's Knight Alzheimer Prevention Initiative and Healthy Aging and Senescence (HAS) Program represent pioneering efforts to understand and prevent age-related neurodegenerative diseases[2]. The institution's strong basic science foundation enables translation of fundamental discoveries into clinical applications.
The Knight Initiative represents a major initiative to understand brain resilience:
Washington University leads multiple major research initiatives:
The movement disorders program investigates:
The Mallinckrodt Institute of Radiology maintains cutting-edge programs:
| Condition | Focus | Phase | Status |
|---|---|---|---|
| Alzheimer's disease | DIAN intervention | Phase 2/3 | Active |
| Alzheimer's disease | Anti-amyloid | Phase 3 | Various |
| Parkinson's disease | Synuclein inhibitor | Phase 2 | Recruiting |
| FTD | Tau antibody | Phase 2 | Enrolling |
| Researcher | H-index | Focus Areas |
|---|---|---|
| John C. M. Morris | 130 | Alzheimer's disease, biomarkers |
| David M. Holtzman | 115 | Alzheimer's disease, amyloid |
| Randall J. Bateman | 90 | Clinical trials, biomarkers |
| Suzanne R. L. Steh | 80 | Parkinson's disease, movement disorders |
Washington University's research benefits from cutting-edge technologies:
WUSTL provides exceptional training in neurodegenerative research:
WUSTL maintains key partnerships:
Washington University research priorities:
Washington University leads the international Dominantly Inherited Alzheimer Network (DIAN), a groundbreaking observational and therapeutic trial studying individuals with genetic mutations causing autosomal dominant Alzheimer's disease[1:1]. DIAN has enrolled over 500 participants from families worldwide with known APP, PSEN1, or PSEN2 mutations, enabling studies of preclinical disease progression and biomarker changes decades before symptom onset.
The DIAN Therapeutic Trials Unit (DTTU) conducts pioneering prevention trials in mutation carriers, testing anti-amyloid and anti-tau therapies before significant cognitive impairment develops. This preventive approach represents a paradigm shift in Alzheimer's disease clinical research[2:1].
The Knight Initiative for Brain Resilience focuses on understanding why some individuals maintain cognitive function despite evidence of neurodegenerative pathology. This research addresses:
Washington University trains the next generation of neurodegeneration researchers through:
The annual Knight Alzheimer's Research Conference brings together international experts to discuss latest advances in the field[3:1].
DIAN. International Research Network. 2024. ↩︎ ↩︎
DIAN Trials. Therapeutic Trials Unit. 2024. ↩︎ ↩︎
Knight Conference. Annual Research Meeting. 2024. ↩︎ ↩︎
Morris JC, et al. Tau and amyloid PET in cognitively normal aging. JAMA Neurol. 2019. ↩︎